Sort
48,018 grants matching “immunotherapy”
Cognate Activation of B-Lymphocytes
$399,750Randolph J. Noelle · Dartmouth College · R37 · FY2009 · AI
Highly Attenuated Vesiculovirus-based Vectors as HBV Therapeutic Vaccines
$399,750Michael D Robek · Albany Medical College · R01 · FY2017 · AI
Understanding ERAP molecular mechanism of MHC I antigen processing
$399,750Marlene Bouvier · University Of Illinois At Chicago · R01 · FY2017 · AI
Highly Attenuated Vesiculovirus-based Vectors as HBV Therapeutic Vaccines
$399,750Michael D Robek · Albany Medical College · R01 · FY2020 · AI
Highly Attenuated Vesiculovirus-based Vectors as HBV Therapeutic Vaccines
$399,750Michael D Robek · Albany Medical College · R01 · FY2019 · AI
Post-translation regulation of Listeria monocytogenes virulence factors
$399,750Nancy Freitag · University Of Illinois At Chicago · R01 · FY2016 · AI
Understanding ERAP molecular mechanism of MHC I antigen processing
$399,750Marlene Bouvier · University Of Illinois At Chicago · R01 · FY2019 · AI
Understanding ERAP molecular mechanism of MHC I antigen processing
$399,750Marlene Bouvier · University Of Illinois At Chicago · R01 · FY2020 · AI
Post-translation regulation of Listeria monocytogenes virulence factors
$399,750Nancy Freitag · University Of Illinois At Chicago · R01 · FY2017 · AI
Project 1: Glutaminolytic GDH1 activation-dependent immunotherapy resistance in LKB1-mutant lung adenocarcinoma
$399,749Sumin Kang · Emory University · P01 · FY2024 · CA
Quantitative oxygen sensing to enable personalized oncology treatment planning
$399,740Gregory Ekchian · Stratagen Bio, Inc. · R43 · FY2021 · CA
Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies
$399,739Jeremy A Elser · Ship Of Theseus, Llc · R41 · FY2025 · CA
PEPTIDE MEDIATED IMMUNOTHERAPY FOR AUTOIMMUNE DISEASE
$399,728Stanford University · R01 · FY2003 · NS
Engineering a potent locally-acting interleukin 12-expressing synthetic self-replicating mRNA to augment responses to anti-PD-1 therapy in neoadjuvant triple negative breast cancer
$399,725Tasuku Kitada · Strand Therapeutics Inc · R43 · FY2021 · CA
Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer
$399,680Adam Shilling · Nanocan Therapeutics Corporation · R42 · FY2022 · CA
Controlled Release of Macromolecules
$399,667Robert S Langer · Massachusetts Institute Of Technology · R37 · FY2012 · EB
Simultaneous Targeting of Tumor and Stroma Cells to Enhance Solid Tumor CAR-T Cell Therapy
$399,658Nicole J. Shirkey-Son · Luminary Therapeutics, Inc. · R43 · FY2021 · CA
Functional signatures of post-infusion CAR T cells for early indication of patient response
$399,625Rebecca L Berdeaux · Cellchorus Inc. · R43 · FY2025 · CA
MR Signal Amplification for Receptor Imaging
$399,623Alexei A Bogdanov · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · EB
Phase II trial of ADXS11-001 vaccine for HPV-related oropharyngeal cancer
$399,622Andrew Sikora · Baylor College Of Medicine · R01 · FY2015 · FD
PLA2G2D Antibodies for Cancer Immunotherapy
$399,618Li-Fen Lee · Apeximmune Therapeutics Inc. · R43 · FY2023 · CA
Development of Lasso Peptides as Potent Endothelin Receptor B Antagonists for Immuno-oncology
$399,609Mark J Burk · Lassogen, Inc. · R43 · FY2021 · CA
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer
$399,586Fatemeh Sadat Majedi · Symphony Biosciences, Inc. · R44 · FY2023 · CA
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
$399,580Jacki Kornbluth · Vanquish Bio Llc · R41 · FY2022 · CA
Platelet Serine/Threonine Phosphatases in Cancer Pathophysiology
$399,554K. Vinod Vijayan · Baylor College Of Medicine · R01 · FY2024 · CA